Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with <scp>CSF</scp> Markers and [<scp><sup>11</sup>C</scp>]<scp>PBR28 PET</scp>
Montelukast crosses the blood-brain barrier at very low levels and is well tolerated and safe in PD patients. Preliminary effects on neuroinflammation and clinical scores motivate a future randomized controlled trial (RCT) in PD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Authors
- Per Svenningsson (ORCID: https://orcid.org/0000-0001-6727-3802)
- Johan Wallin (ORCID: https://orcid.org/0000-0003-0490-9900)
- Anton Forsberg (ORCID: https://orcid.org/0000-0001-8790-3306)
Institutions
- Karolinska Institutet (SE)
Publication Details
- Journal
- Movement Disorders
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1002/mds.30144
- Citations
- 7
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 9.72
Funders
- Kommunfullmäktige, Stockholms Stad
- Karolinska Institutet
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- H. Lundbeck A/S